Kidney Transplantation
📧 Sign up to get email alerts when something new happens for Kidney Transplantation.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-02-27FDA Approved: MYCOPHENOLIC ACID — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for generic mycophenolic acid from Aurobindo Pharma Limited. It is indicated as part of an immunosuppr…
-
FDA approval · 2024-02-07FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for a generic version of mycophenolate mofetil from Hikma Pharmaceuticals USA, enabling continue…
-
CLINICAL_TRIALS research · 2024-02-02Clinical Trial Update: Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial) [Phase 4]
A Phase 4 clinical trial evaluating tacrolimus formulation and its effects on glucose metabolism in kidney transplant recipients with posttr…
-
CLINICAL_TRIALS trial_result · 2023-12-14Clinical Trial Update: PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus [Phase 4]
Phase 4 trial update evaluating pharmacokinetics of switching from twice-daily tacrolimus to once-daily extended-release tacrolimus in diabe…
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients [Phase 4]
Phase 4 trial comparing standard-dose versus reduced-dose tacrolimus with sirolimus in renal transplant patients has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus [Phase 4]
Phase 4 trial comparing reduced versus standard dose cyclosporine with sirolimus in kidney transplant patients assessing graft function; com…
-
CLINICAL_TRIALS trial_result · 2023-12-05Clinical Trial Update: Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING) [Phase 4]
Clinical trial update for a Phase 4 study evaluating treatment of early borderline lesions in low immunological risk kidney transplant patie…
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients [Phase 2]
Phase 2 trial evaluating CMV vaccine HB-101 in kidney transplant patients has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant [Phase 2]
Phase 2 trial evaluating safety and efficacy of dual costimulation blockade with VIB4920 and belatacept to prevent allograft rejection in ad…
-
CLINICAL_TRIALS trial_result · 2023-09-22Clinical Trial Update: Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation [Phase 4]
Phase 4 clinical trial comparing tacrolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and Neoral/sirolimus in adult primary kidney …
-
FDA approval · 2023-09-14FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for PROGRAF (tacrolimus) submitted by Astellas Pharma US, Inc.
-
FDA approval · 2023-09-14FDA Approved: ZORTRESS — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental application for ZORTRESS (everolimus) from Novartis Pharmaceuticals Corporation, expanding its approved indicati…
-
FDA approval · 2023-09-14FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for PROGRAF (tacrolimus) from Astellas, updating the labeling for its use as an immunosuppressant to…
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation [Phase 4]
Phase 4 trial comparing Thymoglobulin, Campath-1H, and Daclizumab in adult living-donor kidney transplantation.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Utilization of Hepatitis C Positive Kidneys in Negative Recipients [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating the use of hepatitis C positive donor kidneys transplanted into hepatitis C negative recipients; study c…
-
CLINICAL_TRIALS trial_result · 2023-09-05Clinical Trial Update: Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies [Phase 3]
Phase 3 clinical trial evaluating induction therapy in sensitized kidney transplant recipients without pre-existing donor-specific antibodie…
-
FDA approval · 2023-05-08FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for mycophenolate mofetil from Ascend Laboratories, LLC under ANDA203005.
-
FDA approval · 2023-05-01FDA Approved: TACROLIMUS — Supplemental Application (Sandoz Inc.)
The FDA approved a supplemental application for tacrolimus by Sandoz Inc., resulting in a supplemental approval for the generic product. Thi…
-
FDA approval · 2023-03-08FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Institutional LLC)
FDA issued a supplemental approval for mycophenolate mofetil in a filing by Mylan Institutional LLC.
-
CLINICAL_TRIALS trial_result · 2023-03-08Clinical Trial Update: Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients [Phase 2, Phase 3]
Phase 2/3 trial updates on sitafloxacin and ertapenem for acute urinary tract infections due to E. coli or Klebsiella in post-kidney transpl…
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients [Phase 2]
Phase 2 trial update for CAMPath and belimumab in sensitized kidney transplant recipients was terminated; results published in 2023.
-
FDA approval · 2022-12-21FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for Lannett's generic mycophenolate mofetil, authorizing its market approval as a generic immunosupp…
-
CLINICAL_TRIALS trial_result · 2022-10-20Clinical Trial Update: The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study [Phase 4]
A Phase 4 prospective pilot study evaluating rifamycin-containing regimens for latent tuberculosis infection in kidney transplant patients, …
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients [Phase 4]
Phase 4 trial investigating pharmacogenomic-guided tacrolimus dosing and monitoring in kidney transplant recipients has completed with resul…
-
CLINICAL_TRIALS trial_result · 2022-04-22Clinical Trial Update: Preserve-Transplant Study [Phase 4]
Phase 4 clinical trial update for the Preserve-Transplant study completed.